Use of pamidronate for osteoporosis treatment in public health care in Brazil
Abstract Purpose: The use of bisphosphonates for osteoporosis is effective in reducing the risk of fractures. However, oral formulations are sometimes not well tolerated or are contraindicated. Due to its availability in Brazilian public health system, pamidronate is frequently prescribed for osteoporosis, despite the lack of studies demonstrating its anti-fracture efficacy and the absence of FDA or EMEA approval for this purpose. The aim of this study was to evaluate the bone mineral density (BMD) response to pamidronate in a group of women with osteoporosis in a tertiary care hospital. Patients and methods: The medical records of women with osteoporosis who received pamidronate for up to two years of treatment were reviewed. Patients were stratified at high or intermediate risk of fracture. Results: A total of 70 women were in treatment with pamidronate. Among them, 74% were at high risk of fracture. A significant gain in spine BMD after 24 months of treatment was observed (p = 0.012). There was no difference between the groups of high and not high risk of fracture. At the femur, no significant increase in BMD was present, though, a strong negative correlation with high PTH levels (r = −0.61; p = 0.003) was seen. In the multivariate analysis BMI at 12 months had impact in the response to the treatment. Conclusion The intravenous pamidronate in a group of postmenopausal women with predominant high risk of fracture promoted an isolated gain in the spine BMD, even though, clinical randomized trials are needed to confirm its anti-fracture efficacy.
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Reumatologia
2017
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600514 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0482-50042017000600514 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0482-500420170006005142017-12-08Use of pamidronate for osteoporosis treatment in public health care in BrazilZanatta,Leila BianchetMarcatto,CristinaRamos,Cassio SlompoMañas,NadilaMoreira,CarolinaBorba,Victoria Pamidronate Bone mineral density Osteoporosis Abstract Purpose: The use of bisphosphonates for osteoporosis is effective in reducing the risk of fractures. However, oral formulations are sometimes not well tolerated or are contraindicated. Due to its availability in Brazilian public health system, pamidronate is frequently prescribed for osteoporosis, despite the lack of studies demonstrating its anti-fracture efficacy and the absence of FDA or EMEA approval for this purpose. The aim of this study was to evaluate the bone mineral density (BMD) response to pamidronate in a group of women with osteoporosis in a tertiary care hospital. Patients and methods: The medical records of women with osteoporosis who received pamidronate for up to two years of treatment were reviewed. Patients were stratified at high or intermediate risk of fracture. Results: A total of 70 women were in treatment with pamidronate. Among them, 74% were at high risk of fracture. A significant gain in spine BMD after 24 months of treatment was observed (p = 0.012). There was no difference between the groups of high and not high risk of fracture. At the femur, no significant increase in BMD was present, though, a strong negative correlation with high PTH levels (r = −0.61; p = 0.003) was seen. In the multivariate analysis BMI at 12 months had impact in the response to the treatment. Conclusion The intravenous pamidronate in a group of postmenopausal women with predominant high risk of fracture promoted an isolated gain in the spine BMD, even though, clinical randomized trials are needed to confirm its anti-fracture efficacy.info:eu-repo/semantics/openAccessSociedade Brasileira de ReumatologiaRevista Brasileira de Reumatologia v.57 n.6 20172017-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600514en10.1016/j.rbre.2016.07.005 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Zanatta,Leila Bianchet Marcatto,Cristina Ramos,Cassio Slompo Mañas,Nadila Moreira,Carolina Borba,Victoria |
spellingShingle |
Zanatta,Leila Bianchet Marcatto,Cristina Ramos,Cassio Slompo Mañas,Nadila Moreira,Carolina Borba,Victoria Use of pamidronate for osteoporosis treatment in public health care in Brazil |
author_facet |
Zanatta,Leila Bianchet Marcatto,Cristina Ramos,Cassio Slompo Mañas,Nadila Moreira,Carolina Borba,Victoria |
author_sort |
Zanatta,Leila Bianchet |
title |
Use of pamidronate for osteoporosis treatment in public health care in Brazil |
title_short |
Use of pamidronate for osteoporosis treatment in public health care in Brazil |
title_full |
Use of pamidronate for osteoporosis treatment in public health care in Brazil |
title_fullStr |
Use of pamidronate for osteoporosis treatment in public health care in Brazil |
title_full_unstemmed |
Use of pamidronate for osteoporosis treatment in public health care in Brazil |
title_sort |
use of pamidronate for osteoporosis treatment in public health care in brazil |
description |
Abstract Purpose: The use of bisphosphonates for osteoporosis is effective in reducing the risk of fractures. However, oral formulations are sometimes not well tolerated or are contraindicated. Due to its availability in Brazilian public health system, pamidronate is frequently prescribed for osteoporosis, despite the lack of studies demonstrating its anti-fracture efficacy and the absence of FDA or EMEA approval for this purpose. The aim of this study was to evaluate the bone mineral density (BMD) response to pamidronate in a group of women with osteoporosis in a tertiary care hospital. Patients and methods: The medical records of women with osteoporosis who received pamidronate for up to two years of treatment were reviewed. Patients were stratified at high or intermediate risk of fracture. Results: A total of 70 women were in treatment with pamidronate. Among them, 74% were at high risk of fracture. A significant gain in spine BMD after 24 months of treatment was observed (p = 0.012). There was no difference between the groups of high and not high risk of fracture. At the femur, no significant increase in BMD was present, though, a strong negative correlation with high PTH levels (r = −0.61; p = 0.003) was seen. In the multivariate analysis BMI at 12 months had impact in the response to the treatment. Conclusion The intravenous pamidronate in a group of postmenopausal women with predominant high risk of fracture promoted an isolated gain in the spine BMD, even though, clinical randomized trials are needed to confirm its anti-fracture efficacy. |
publisher |
Sociedade Brasileira de Reumatologia |
publishDate |
2017 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0482-50042017000600514 |
work_keys_str_mv |
AT zanattaleilabianchet useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil AT marcattocristina useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil AT ramoscassioslompo useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil AT manasnadila useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil AT moreiracarolina useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil AT borbavictoria useofpamidronateforosteoporosistreatmentinpublichealthcareinbrazil |
_version_ |
1756413332800143360 |